Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

T14.SI

SES

2.53

USD

+0.07(+2.85%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

6.32

Price/Book

3.15

Debt/Equity

0.93%

Return on Equity

30.83%

Dividend Yield

3.78%

EBITDA

2.74B

Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited, together with its subsidiaries, produces and sells traditional Chinese medicine, western medicine, and healthcare products primarily in the People's Republic of China. It operates in Chinese Medicine and Western Medicine segments. The company is also involved in the manufacture and sale of Chinese and western pharmaceutical and biological products; wholesale and retail sale of medicines, biochemical pharmaceutical products, and daily use products; and operation of hospitals. In addition, it provides logistics, stocks, equipment installation, and medicine processing services; medicine inspection and testing services; and pharmaceutical consultancy services. The company sells its medicinal products under its own brand to the wholesalers; and purchases medicinal products under other brands from distributors and sells these to other wholesalers. The company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited and changed its name to Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited in May 2022. Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited was incorporated in 1992 and is based in Tianjin, the People's Republic of China.

Statements Highlights

AnnualQuarterly

Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024
Total Revenue	6,603,652,015	6,907,544,256	8,249,249,565	8,222,311,849	7,306,736,058
Gross Profit	2,575,896,849	2,757,119,957	3,293,657,692	3,618,228,454	3,520,721,047
Operating Income	785,175,879	866,676,481	980,049,636	1,096,975,382	2,566,726,495
Net Income	661,704,350	769,144,377	861,793,906	986,707,377	2,229,334,236
Total Assets	8,283,387,680	9,067,085,006	10,156,982,039	10,230,100,940	10,768,625,044
Total Current Liabilities	2,163,851,493	2,433,902,114	3,333,434,867	3,232,922,380	2,817,836,829
Total Equity	5,949,894,020	6,513,829,130	6,551,953,137	6,645,236,506	7,849,936,326
Free Cash Flow	482,258,430	695,452,727	569,343,255	547,560,170	806,859,405
Cash from Operations	671,420,832	852,401,231	677,245,078	688,487,880	924,672,004
Cash from Investing	73,771,349	-311,851,997.16	-12,279,784.15	-744,213,235	342,305,198
Cash from Financing	-237,260,669.17	-244,701,910.06	-236,619,609.63	-836,649,162	-319,888,287.29
Net Change in Cash	507,931,513	295,847,324	428,351,660	-714,147,279	947,046,824